Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOLIPANC neoadjuvant nal-IRI + oxaliplatin + 5-FU/folinic acid in hepatic oligometastatic pancreatic cancer
DRKS00027122Phase 2Recruiting
- Sponsor
- University Hospital Cologne
- Start
- Nov 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanoliposomal irinotecan, oxaliplatin, fluorouracil and folinic acid in pancreatic adenocarcinoma (PDAC), liver cancer and secondary malignant neoplasm of intrahepatic bile duct, sponsored by University Hospital Cologne. Primary endpoints: Efficacy of neoadjuvant nal-IRI + oxaliplatin + 5-FU/folinic acid, Safety of neoadjuvant nal-IRI + oxaliplatin + 5-FU/folinic acid and 1 more. Started Nov 2021; status: recruiting.
02
Drugs
nanoliposomal irinotecanoxaliplatinfluorouracilfolinic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)liver cancersecondary malignant neoplasm of intrahepatic bile duct
Beyond the preview
Go deeper on DRKS00027122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00027122.